MNG1088
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.550
- INTERFERON_GAMMA_RESPONSE+0.417
- DNA_REPAIR+0.321
- P53_PATHWAY+0.266
- APICAL_SURFACE+0.217
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.178
- CHOLESTEROL_HOMEOSTASIS+0.168
- APOPTOSIS+0.140
- TNFA_SIGNALING_VIA_NFKB+0.135
- PEROXISOME+0.131
Top 10 suppressed
- TGF_BETA_SIGNALING-0.235
- KRAS_SIGNALING_UP-0.226
- UV_RESPONSE_DN-0.221
- NOTCH_SIGNALING-0.189
- SPERMATOGENESIS-0.188
- PROTEIN_SECRETION-0.184
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.160
- HYPOXIA-0.143
- MYC_TARGETS_V1-0.141
- IL2_STAT5_SIGNALING-0.139
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG153 | — | — | 0.708 |
| 2 | MBCProject_2517_T1_RNA | — | B | 0.687 |
| 3 | TCGA-A8-A07Z-01A-11R-A00Z-07 | — | B | 0.687 |
| 4 | R36 | — | — | 0.658 |
| 5 | ERR2278877 | — | — | 0.644 |
| 6 | TCGA-BH-A6R8-01A-21R-A33J-07 | — | B | 0.644 |
| 7 | TCGA-EW-A1P5-01A-11R-A144-07 | — | B | 0.639 |
| 8 | TCGA-A2-A04X-01A-21R-A034-07 | — | C | 0.639 |
| 9 | DRR168511 | — | — | 0.632 |
| 10 | MBCProject_2741_T1_RNA | — | B | 0.631 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.550 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.417 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.321 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.266 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.217 | Temsirolimus | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.178 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.168 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.140 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.135 | Inavolisib | — uncovered |
| PEROXISOME | 0.131 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.121 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.116 | Temsirolimus | — uncovered |
| APICAL_JUNCTION | 0.106 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.102 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.099 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.094 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.086 | Inavolisib | — uncovered |
| MYOGENESIS | 0.081 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.066 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.064 | Inavolisib | — uncovered |